Safety of omalizumab in people with chronic urticaria during COVID-19

Summaries 3 min 566

Font Size

Created On: 15/07/2022

The focus of this research was to see how omalizumab therapy affected patients with chronic spontaneous urticaria (CSU) during the SARS-CoV-2 outbreak.

See All

Key take away

During COVID-19, omalizumab is safe to use in CSU people and does not increase the risk of COVID-related infections, hospitalization, or pneumonia.

Background

The focus of this research was to see how omalizumab therapy affected patients with chronic spontaneous urticaria (CSU) during the SARS-CoV-2 outbreak.

Method

The research comprised a total of 370 patients with CSU.

Result

Out of 370, 60 (16.2%) patients were reported to be affected by COVID-19. Pneumonia and hospitalization rates were 4.1 percent and 1.9 percent, respectively. In terms of SARS-CoV-2 (+) and SARS-CoV-2 associated pneumonia and hospitalization, there was no notable change between CSU patients who received omalizumab therapy and those who did not receive omalizumab. Serum IgE levels, gender, CSU duration, omalizumab therapy, and atopy were not found to be linked with a raised risk for SARS-CoV-2 positivity in CSU people.

Conclusion

To summarize, omalizumab showed no risk of SARS-CoV-2 infection, COVID-19-related pneumonia, or hospitalizations in CSU patients, adding support to the idea that omalizumab can be safely utilized in CSU patients during COVID-19.